http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022087255-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9e4f06125ad5e5f5cc1a5b339316a4c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| filingDate | 2021-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_085db491fcdf23d7077c41a3e1320c16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c931309d59831091eed744e02baf50d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae9d5fc354cd0657142497be5e7e2ec7 |
| publicationDate | 2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022087255-A2 |
| titleOfInvention | Coronavirus spike glycoprotein with improved expression and stability |
| abstract | The present invention includes a mutant coronavirus spike protein, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an S1 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the resulting mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. In one example, the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Current SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e. B.1.621), and others. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113150085-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115850399-A |
| priorityDate | 2020-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 891.